Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00491608
Other study ID # 499F04
Secondary ID
Status Completed
Phase Phase 3
First received June 22, 2007
Last updated January 11, 2012
Start date June 2007
Est. completion date July 2008

Study information

Verified date January 2012
Source ZymoGenetics
Contact n/a
Is FDA regulated No
Health authority United States: Food and Drug Administration
Study type Interventional

Clinical Trial Summary

The purpose of this study is to evaluate the safety and immune system response to recombinant thrombin when used to control bleeding in spinal and vascular surgery.


Description:

This is a Phase 3b, open-label, single-group, multisite safety and immunogenicity study of recombinant thrombin (rThrombin) in participants who are at least 18 years of age and undergoing spinal or vascular surgery. Eligible participants will receive topical rThrombin during surgery and complete a 1-month follow-up visit.


Recruitment information / eligibility

Status Completed
Enrollment 234
Est. completion date July 2008
Est. primary completion date July 2008
Accepts healthy volunteers No
Gender Both
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Currently undergoing cervical, thoracic, or lumbar discectomy; corpectomy, laminectomy, lateral or interbody fusion, including both anterior and posterior approaches (not including minimally invasive procedures; arterial reconstruction; peripheral artery bypass (PAB) grafting; or arteriovenous (AV) vascular access procedures

- History of surgery with high likelihood of exposure to bovine thrombin within the past 3 years. Prior surgery must have been 1 of the following open procedures: open procedures involving the spine or cranium, PAB grafting, AV vascular access procedures, autologous skin grafting, or other surgical procedure accompanied by documented treatment with bovine thrombin

- Age of 18 years or younger at time of informed consent

- If female and of child-bearing potential: Negative pregnancy test result within 14 days prior to treatment

- Use of a medically accepted form of contraception from the time of informed consent to completion of all follow-up study visits, if sexually active male or a sexually active female of childbearing potential

- Signed IRB/independent ethics committee-approved informed consent document

Exclusion Criteria:

- Currently undergoing procedures requiring cardiopulmonary bypass or involving the aortic arch

- Known hypersensitivity to rThrombin or any of its components

- Presence of medical, social, or psychosocial factors that, in the opinion of the investigator, could impact safety or compliance with study procedures

- Breastfeeding

- Receipt of treatment with any experimental agent within 30 days of study enrollment or treatment

Study Design

Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Biological:
rThrombin
1000 U/mL applied directly or in combination with absorbable gelatin sponge or powder

Locations

Country Name City State
United States Huntington Memorial Hospital Pasadena California

Sponsors (1)

Lead Sponsor Collaborator
ZymoGenetics

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Number of Participants With Anti-recombinant Thrombin (rThrombin) Product Antibodies at Day 29 in Participants With and Without Anti-bovine Thrombin Product Antibodies at Baseline Seropositive=with specific anti-bovine thrombin product antibodies; seronegative=without specific anti-bovine thrombin product antibodies. At Day 29 Yes
Secondary Number of Participants With Death as Outcome, Serious Adverse Events, Treatment-related Adverse Events (AEs), and Treatment-emergent AEs AE=a new unfavorable symptom, sign, or disease or worsening of a preexisting condition that may or may not have a causal relationship with treatment. SAE=an unfavorable medical event that results in death, persistent or significant incapacity, or drug dependency or abuse; is life-threatening, or a congenital anomaly/birth defect; or requires or prolongs hospitalization. Treatment-related=possibly, probably, or certainly related to study drug. Treatment-emergent=onset on or after treatment start. Grade (Gr) 1=mild, Gr 2=moderate, Gr 3=severe, Gr 4=life threatening/disabling, Gr 5=death. Day 1 (surgery) to Day 29 (end of study), continuously Yes
Secondary Number of Participants With Abnormal Hematology Laboratory Results of Common Terminology Criteria (CTC) Grade 2 or Higher at Baseline and Day 29 Hemoglobin, low (g/L): Grade 2=<100 Grade 3=<80; Grade 4=<65. Platelets, low: Grade 2=<75*10^9/L; Grade 3=<50*10^9/L; Grade 4=<25*10^9/L. Leukocytes, low: Grade 2=<3.0-2.0*10^9/L; Grade 3=<2.0-1.0*10^9/L; Grade 4=<1.0*10^9/L. Lymphocytes, low: Grade 2=<0.8*10^9/L; Grade 3=<0.5*10^9/L; Grade 4=<0.2*10^9/L. Neutrophils, low: Grade 2=<1.5*10^9/L; Grade 3=<1.0*10^9/L; Grade 4=<0.5*10^9/L. Changes in hematocrit values observed were not graded for severity. Baseline and Day 29 (end of study) Yes
Secondary Number of Participants With Elevations in Coagulation Parameters of CTC Grade 3 or Higher at Baseline and Day 29 Activated partial thromboplastin time (aPTT) elevations: Grade 3=>2*upper limit of normal (ULN). International normalized ratio(INR)elevations: Grade 3=>2*ULN. Changes in prothrombin time were not graded for toxicity. n=Number of participants with assessments available at that visit. Baseline and Day 29 (end of study) Yes
Secondary Number of Participants With Abnormal Laboratory Results in Median Levels of Immunoglobulin A, G, and M at Baseline or Day 29 Abnormal laboratory findings were recorded as AEs when the investigator considered them to be clinically significant (eg, an unusual result for the surgical population or for an individual participant) or when they were associated with symptoms or required treatment or a change in patient management. Baseline and Day 29 (end of study) Yes
Secondary Number of Participants With Clinically Significant Changes in Mean Values for Vital Signs (Temperature, Systolic Blood Pressure, Diastolic Blood Pressure, Respiration Rate, Heart Rate) at Baseline and Day 29 Laboratory findings considered clinically significant by investigator when associated with symptoms, required specific treatment, or required a change in participant management. Clinically significant changes in vital signs were reported as adverse events. Baseline and Day 29 (end of study) Yes
See also
  Status Clinical Trial Phase
Completed NCT05023850 - Comparing Thoracolumbar Interfascial Plane Block With Erector Spinae Plane Block N/A
Completed NCT01251042 - Comparison Between Return and Wastage of Your Own Blood, Collected During Spinal Surgery, for Verification of Safety When Returning Blood N/A
Completed NCT01356082 - CNAP™ Monitor Study N/A
Completed NCT06323694 - Quality of Life, Expectations, Thoughts and Fears of Patients on the Waiting List for Spinal Surgery
Recruiting NCT04370951 - Efficacy of the Erector Spinae Plane Block in Posterior Thoraco- Lumbar Spinal Decompression Surgery N/A
Completed NCT03069794 - Effect of Spinal Surgery on the Posture and the Balance of the Patients Reached of Spinal Pathologies N/A
Recruiting NCT02595788 - Haemodynamic Changes During Anaesthesia in the Prone Position, Evaluated Using Transoesophageal Ultrasound N/A
Completed NCT01855542 - The Aim of This Investigation is to Compare the Influence of 0.9% Saline and Plasmalyte Solution on Acid-base Balance and Electrolytes in Healthy Patients Undergoing Major Spine Surgeries. N/A
Not yet recruiting NCT01299818 - Assessment of Central Pain in Patients Who Undergo Spinal Surgery and Influence in Surgery Outcome N/A
Recruiting NCT05417100 - Understanding How Methadone Treatment During Surgery Affects Pain Levels and the Need for Pain Medications After Surgery Phase 3
Terminated NCT03160170 - Efficacy of Suction Enabled Retraction Device N/A
Not yet recruiting NCT06466083 - Correlation Analysis of POD and PND in Elderly Spinal Surgery Patients Based on Rs-fMRI
Recruiting NCT06451627 - Esketamine on Postoperative Sleep Disturbance of Patients Undergoing Spinal Surgery N/A
Not yet recruiting NCT04922359 - Effect of Perioperative Lidocaine on Gastrointestinal Function Recovery After Lumbar Spine Surgery in Adults N/A
Recruiting NCT04189172 - MiDura-Study (Neuro-Patch in Duraplasty)
Recruiting NCT05553028 - Study Comparing Arthrodesis Technique of Thoracic and/or Lumbar Spine by Posterior Approach Performed by Robot-assisted Surgery (Robot Mazor X Stealth ™) Versus Conventional Surgery N/A
Completed NCT02892617 - Evaluation of the Prevalence of Germs Slow Growth in the Intervertebral Disc (IVD) During Spinal Surgery N/A
Completed NCT06118489 - Effects of Different Anesthetic Gases on Hemodynamics, Arterial Oxygenation and Lung Mechanics
Recruiting NCT03512379 - Clinical Trial for the Application of Robotic System in Spinal Surgery N/A
Recruiting NCT03501810 - Study Assessing Safety and Performance of OrtoWell Distractor in Patients Undergoing Spinal Surgery